Establishment Labs Holdings Inc. (NASDAQ:ESTA) Short Interest Up 14.5% in October

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) saw a significant growth in short interest in October. As of October 15th, there was short interest totalling 5,280,000 shares, a growth of 14.5% from the September 30th total of 4,610,000 shares. Based on an average daily volume of 376,600 shares, the short-interest ratio is currently 14.0 days. Approximately 23.2% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ESTA. Citigroup boosted their price objective on shares of Establishment Labs from $45.00 to $50.00 and gave the company a "neutral" rating in a report on Tuesday, October 1st. Stephens restated an "overweight" rating and set a $68.00 price objective on shares of Establishment Labs in a research note on Wednesday, August 7th. JPMorgan Chase & Co. decreased their target price on shares of Establishment Labs from $61.00 to $50.00 and set an "overweight" rating for the company in a research note on Wednesday, August 7th. Finally, BTIG Research boosted their price target on Establishment Labs from $62.00 to $65.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $58.83.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets boosted its stake in shares of Establishment Labs by 32,968.7% in the 1st quarter. BNP Paribas Financial Markets now owns 97,222 shares of the company's stock valued at $4,949,000 after purchasing an additional 96,928 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Establishment Labs during the 1st quarter worth approximately $4,185,000. Divisadero Street Capital Management LP purchased a new position in Establishment Labs in the second quarter worth $5,829,000. Principal Financial Group Inc. purchased a new position in shares of Establishment Labs in the 2nd quarter worth about $593,000. Finally, Bayesian Capital Management LP bought a new position in shares of Establishment Labs during the 1st quarter valued at approximately $631,000. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Establishment Labs Price Performance

ESTA traded up $0.08 during trading on Tuesday, hitting $44.84. 117,315 shares of the stock traded hands, compared to its average volume of 374,579. The business has a 50 day moving average price of $43.18 and a 200 day moving average price of $46.12. The company has a debt-to-equity ratio of 4.30, a current ratio of 4.44 and a quick ratio of 2.91. Establishment Labs has a twelve month low of $16.96 and a twelve month high of $60.12. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -14.42 and a beta of 1.20.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). The business had revenue of $44.12 million during the quarter, compared to analyst estimates of $43.10 million. Establishment Labs had a negative net margin of 54.97% and a negative return on equity of 220.67%. The business's quarterly revenue was down 9.2% compared to the same quarter last year. During the same period last year, the business earned ($0.65) earnings per share. Equities research analysts forecast that Establishment Labs will post -2.27 earnings per share for the current fiscal year.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.